FORGE meets Sulis Therapeutics to discuss new STING-targeted therapy
On 3rd February 2026, FORGE met with the senior team from Sulis Therapeutics to hear about their latest research targeting the STING pathway, which plays an important role in autoimmune and inflammatory diseases including SAVI.
The Head of R&D at Sulis Tx shared promising preclinical results with us including research on cells taken from SAVI patients. Their approach, which is highly original, aims to remove STING-associated inflammatory change whilst preserving normal immune function. In animal models, the specific STING-targeting treatment they have devised, impressively reduced inflammation and organ damage resulting in improved survival. The therapy was also well tolerated.
The company is now seeking funding to take this research forward into phase 1 human trials and expressed interest in working closely with FORGE and the patient community. Further discussions are planned to explore future collaboration.